Abstract: There is described an adhesive dressing comprising a backing layer having a pressure sensitive adhesive layer over one surface thereof, a pad adhered to a portion of the adhesive layer a removable protector which covers the remainder of the adhesive layer and a conformable support layer which is lightly attached to the non-adhesive surface of the backing layer characterised in that the removable protector is provided with an aperture through which the pad is adhered to the adhesive layer.

Abstract: A percutaneous absorption preparation which is excellent in the skin penetration of a non-narcotic analgesic buprenorphine and can sustain a high blood level in a stable state over a long period of time is provided. The percutaneous absorption preparation for administrating buprenorphine hydrochloride and/or buprenorphine, which comprises a support having on one surface thereof a plaster layer containing a pressure-sensitive adhesive, buprenorphine hydrochloride and/or buprenorphine, and a penetration enhancer, wherein the penetration enhancer comprises a combination of a monoglyceride of a fatty acid having 6 to 8 carbon atoms and isopropyl myristate, and the plaster layer contains at least 10% by weight of a monoglyceride off fatty acid having 6 to 8 carbon atoms and at least 5% by weight off isopropyl myristate, with the proviso that the content of the whole penetration enhancer ranges from 25 to 50% by weight.

Abstract: Methods and devices for preventing an adverse reaction of the skin to the presence of a skin-sensitizing agent by administering an effective amount of a potassium-sparing diuretic.

Abstract: A crosslinked, acrylate-based pressure-sensitive adhesive is provided to obtain a creep compliance value of the pressure-sensitive adhesive of between 1.1.times.10.sup.-5 cm.sup.2 /dyne and 2.3.times.10.sup.-5 cm.sup.2 /dyne in the presence of alcohol-based excipients, such as ethanol serving as a solvent or a penetration enhancing agent used with transdermal delivery devices. The method of preparing such crosslinked pressure-sensitive adhesive by using electron beam radiation of from 5 kGy to 200 kGy, and medical articles using the crosslinked pressure-sensitive adhesive as a layer therein to contact skin are also provided.

Abstract: A nutrient or medicinal composition for administration to ruminants, which comprises one or more biologically active substances coated with a composition comprising a chitosan salt and at least one fat.

Abstract: A diltiazem pellet formulation for oral administration comprises a core of diltiazem or a pharmaceutically acceptable salt thereof in association with an organic acid, and a multi-layer membrane surrounding the core and containing a major proportion of a pharmaceutically acceptable film-forming, water insoluble synthetic polymer and a minor proportion of a pharmaceutically acceptable film-forming, water soluble synthetic polymer. The number of layers in the membrane and the ratio of the water soluble to water insoluble polymer being effective to permit release of the diltiazem from the pellet at a rate allowing controlled absorption thereof over a twenty four hour period following oral administration.

Abstract: The invention relates to the use of estriol as the sole active ingredient for the production of a transdermal medicament which continuously releases the active ingredient for the treatment of climacteric osteoporosis. It has been shown according to the invention that estriol, which has up until now been thought ineffective for the treatment of climacteric osteoporosis, develops strong anti-osteoporotic effectiveness upon continuous transdermal application.

Abstract: A high molecular weight drug is transdermally administered by applying a polymer skin enhancer and a drug active to the skin of the patient. The drug active has a molecular weight of above 500 daltons. The drug may be encapsulated or the drug solution may be partly encapsulated and partly free. The skin enhancer is preferably polyvinylpyrrolidone (PVP) and it is mixed at between 7 and 35% of the drug. A gelling agent may be optionally added at up to 20% by volume. The chemical system is preferably administered via a multidose transdermal drug patch assembly which includes a drug-impervious support impressed to form a series of compartments. Each compartment is a reservoir for a unit dose of a drug active to be transdermally administered. The support is adhesively secured to the skin of a patient. Individual devices are provided for resealably enclosing the drug active in each of the reservoirs.

Abstract: A transdermal drug delivery device involving an acrylate or methacrylate based adhesive copolymer, a skin penetration enhancer, and a therapeutically effective amount of alfuzosin.

Abstract: A device for the transdermal administration of oxybutynin comprising a microporous tie layer located between the oxybutynin reservoir and the contact adhesive. The tie layer eliminates blooming and delamination and has no appreciable adverse effect on either the oxybutynin flux or release rate from the device.

Abstract: An improved transdermal delivery composition is provided comprising a low molecular weight fatty acid, characterised in that it further comprises a long chain fatty acid or a long chain fatty acid lower alkyl ester, wherein the long chain is a C.sub.13 to C.sub.21 chain and preferably contains at least one cis-olefinic bond. Preferred long chain components are oleic acid and ethyl oleate while the preferred low molecular weight fatty acid is propionic acid. The compositions are particularly effective at transdermally delivering physostigmine and its analogues in a stable dosaged manner.

Abstract: The present invention relates to an improvement in an osmotic delivery device wherein the device comprises a semipermeable wall comprising cellulose acetate butyrate and surrounding an internal compartment containing a beneficial agent or medicament formulation, a fluid-activated expandable driving member, optionally a partition layer between the agent formulation and the driving member, and, optionally a density member, and exit means in the semipermeable wall; and wherein the improvement comprises the cellulose acetate butyrate component of the semipermeable wall having a differential scanning calorimetry ("DSC") profile wherein the main or primary DSC peak has a minimum temperature peak above 228.degree. C. and the secondary DSC peak area is equal to or less than about 30% of the total combined areas of the primary and secondary DSC peaks.

Abstract: An external anti-inflammatory and analgesic plaster preparation includes as an active ingredient a salt of diclofenac, 2[(2,6-dichlorophenyl)amino]benzene-acetic acid, with a cyclic organic having the general formula (I): ##STR1## wherein X is a group of the formula --(CH.sub.2)m-- in which m is an integer of 0 or 1 and n is an integer of 2 and a pH value of the preparation is adjusted to a range of 7.3 to 9.0.

Abstract: The present invention relates to an improvement in an osmotic delivery device wherein the device comprises a semipermeable wall comprising cellulose acetate butyrate and surrounding an internal compartment containing a beneficial agent or medicament formulation, a fluid-activated expandable driving member, optionally a partition layer between the agent formulation and the driving member, and, optionally a density member, and exit means in the semipermeable wall; and wherein the improvement comprises the cellulose acetate butyrate component of the semipermeable wall having a differential scanning calorimetry ("DSC") profile wherein the main or primary DSC peak has a minimum temperature peak above 228.degree. C. and the secondary DSC peak area is equal to or less than about 30% of the total combined areas of the primary and secondary DSC peaks.

Abstract: Transdermal preparations containing as active ingredient toremifene or one of its metabolites N-demethyltoremifene or 4-hydroxy-toremifene or their pharmaceutically acceptable non-toxic salts are useful for the treatment of cancers localized in the skin or on a short distance form the skin such as metastatic lesions of breast cancer. They may also be used in adjuvant therapy of breast cancer and in the reversal of multidrug resistance of cancer cells to cytotoxic drugs. Such transdernal preparations are of particular interest in the treatment of melanoma, lymphoma, Kaposi's sarcoma and fungoides mycosis.

Abstract: A method of pigmenting certain parts and products of poultry, fish and crustacea by including in the feed of the pertinent animal one or more of the carotenoids 2'-dehydroplectaniaxanthin, desmethylspheroidenone, spheroidenone, 1-hydroxy-3,4-didehydro-1,2-dihydro-.psi.,.psi.-caroten-2-one, 5'-hydroxy-5',6'-dihydro-4'-apo-.beta.-caroten-6'-one, 1'-hydroxy-3',4'-didehydro-1',2'-dihydro-.beta.,.psi.-carotene-4,2'-dione and 5'-hydroxy-5',6'-dihydro-4'-apo-.beta.-carotene-4,6'-dione, poultry, fish and crustacea feeds for pigmenting certains parts and products of these animals, beadlets and premixes for adding to poultry, fish and crustacea feeds, and the carotenoids 1-hydroxy-3,4-didehydro-1,2-dihydro-.psi.,.psi.-caroten-2-one, 5'-hydroxy-5',6'-dihydro-4'-apo-.beta.-caroten-6'-one, 1'-hydroxy-3',4'-didehydro-1',2'-dihydro-.beta.,.psi.-carotene-4,2'-dione and 5'-hydroxy-5',6'-dihydro-4'-apo-.beta.-carotene-4,6'-dione.

Abstract: The present invention relates to a new self-adhesive transdermal matrix system for the administration of a hormone by percutaneous route, said system which comprises a support and self-adhesive matrix, having a matrix comprising:(a) 40 to 60 parts by weight of an ethylene/vinyl acetate copolymer,(b) 5 to 20 parts by weight of a cellulosic material,(c) 35 to 55 parts by weight of at least one compound selected from the group consisting of: crotamiton, N-substituted 2-pyrrolidones of the formula I, ##STR1## in which the R group represents a (C.sub.1 -C.sub.15)-alkyl, cyclohexyl or 2-hydroxyethyl group, and higher C.sub.12 -C.sub.20 aliphatic alcohols, and(d) 0,01 to 7 parts by weight of a hormone selected from the group consisting of estrogen components, progestogen components and mixtures thereof.It also relates to a method for preparing this transdermal matrix system.

Abstract: A method of preparing a patch for the controlled release of readily available volatile active substances to the skin is disclosed. The patch comprises a back layer, and, bonded to the back layer, a water-insoluble adhesive film consisting of a pressure-sensitive fusion adhesive, plus a detachable film covering the adhesive film. The pressure-sensitive fusion adhesive contains a triple-block copolymer of polystyrene block copoly(ethylene/butylene) block polystyrene at a concentration of 10 to 80% by wt., and an active substance at a concentration of 2.5 to 25% by weight, which is a readily volatile liquid at the temperature at which the adhesive bonds.

Abstract: A skin or buccal patch for providing nicotine replacement therapy which comprises a matrix type laminated composite in which the matrix is composed of a mixture of nicotine in a polymer wherein the amount of nicotine in the matrix, diffusion coefficient of nicotine in the matrix and the thickness of matrix are such that the release of nicotine is: (1) controlled by the patch; (2) rapid and at a relatively high flux over the prescribed wearing time of patch; and (3) such that a substantial proportion of the nicotine initially in the patch has been released at the end of the prescribed wearing time.

Abstract: A dosage form is disclosed for delivering pentoxifylline to a patient in need of pentoxifylline therapy. A method is discussed for delivery pentoxifylline to a patient at a dosage form controlled rate over an extended period of time.